Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02188758 · ClinicalTrials.gov registry record
Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment
A clinical trial, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- 20
- Enrollment target
NCT02188758 is a clinical trial that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT02188758 has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The goal of this study is to identify chemical compounds in the blood and sputum (i.e., biomarkers) that are associated with objective measurements of health status in patients with cystic fibrosis (CF). This study builds upon observations that blood levels of hepcidin-25, a protein that regulates how the body uses and stores iron, vary during CF pulmonary exacerbation (CFPE).
Interventions
- OTHER Adults - CFPE Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-07 |
| Est. Completion | 2018-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02188758
The ClinicalTrials.gov registry entry for NCT02188758 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adults - CFPE Treatment is the first listed.
NCT02188758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02188758 about?
NCT02188758 is a clinical study titled "Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment". The goal of this study is to identify chemical compounds in the blood and sputum (i.e., biomarkers) that are associated with objective measurements of health status in patients with cystic fibrosis (CF). This study builds upon observations that blood levels of hepcidin-25, a protein that regulates h...
What is the current status of trial NCT02188758?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2014-07. Estimated completion is 2018-01.
What interventions are being tested in trial NCT02188758?
The interventions under investigation include: Adults - CFPE Treatment (OTHER).
Who is sponsoring clinical trial NCT02188758?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.